Stem cell therapy prices vary between clinics in Japan because the quotes often cover different treatments, different amounts of medical work, or different numbers of treatment sessions. Public MHLW documents show about ¥1,000,000 for one knee using 100 million autologous adipose-derived MSCs, ¥1,400,000 including tax per 100-million-cell administration in another knee plan, and ¥1,800,000 before tax per treatment in a chronic-pain plan.[1][2][3]
¥1.4 million is 40% higher than ¥1.0 million, while ¥1.8 million is 80% higher. Those figures do not show that one treatment is 40% or 80% better. The conditions being treated, pricing units, cell-processing steps, included services, and treatment schedules are different.
When comparing stem cell treatment costs in Japan, check the cell source, dose, price unit, number of treatments, collection and culture costs, tests, storage, follow-up, refund rules, tax, and international-patient fees before deciding which quote is lower.
Check These Cost Items
| Price factor | What to check |
|---|---|
| Cell source | Your own cells or donor-derived cells |
| Collection | Fat collection, bone marrow collection, or no personal collection |
| Processing | Isolation, culture, expansion, testing, storage, and transport |
| Cell dose | Number of cells planned for each administration |
| Price unit | Per knee, joint, injection, infusion, session, or full course |
| Treatment count | One administration or several |
| Testing | Blood work, infection screening, imaging, and specialist review |
| Follow-up | Later visits, tests, imaging, or remote checks |
| International support | Interpretation, translation, coordination, and related services |
For an autologous cultured-cell treatment, the bill may cover several separate stages:
medical review → testing → cell collection → cell processing → cell administration → follow-up.
A clinic that includes all six stages in one quote can look more expensive than a clinic that shows only the administration fee. Compare the same stages before comparing the total.
Run the Total Cost
| Example | Simple calculation | What it shows |
|---|---|---|
| ¥1.0m vs ¥1.4m | 40% headline difference | Same stated 100-million-cell count does not mean the same price |
| ¥1.0m vs ¥1.8m | 80% headline difference | Different indications and treatment plans should not be compared by price alone |
| ¥1.0m treatment + ¥100,000 repeat collection | ¥1.1m | The listed repeat-collection fee adds 10% to the original headline figure |
| 2 × ¥1.8m treatments | ¥3.6m before tax | A per-treatment price can become much larger over a course |
| 3 × ¥1.8m treatments | ¥5.4m before tax | The number of administrations can matter more than the first advertised price |
These calculations use prices stated in specific public treatment documents. They are not Japanese average prices and should not be used as a personal treatment estimate.
Confirm the Cell Type
Two clinics can both call a treatment “MSC therapy” while using different cells. One may use the patient’s own adipose-derived MSCs. Another may use donor-derived cells. The collection, processing, storage, and administration costs can therefore be different before the cells even reach the patient.
PRP, exosomes, and stem cells should not be put into the same price comparison either. PRP is prepared from blood to produce platelet-rich plasma. Exosome products do not contain living stem cells. The FDA also discusses stem cell products and exosome products separately.[8]
A ¥500,000 exosome treatment and a ¥1,500,000 cultured-cell treatment are not simply cheaper and more expensive versions of the same procedure.
Check the Pricing Basis
The three treatment plans used for the price examples in this article are self-pay treatments. The MHLW documents for the two knee examples state that public health insurance does not cover the treatment and that the patient bears the full cost.[1][2]
MHLW also publishes a pricing manual for medical institutions treating visiting foreign patients on a self-pay basis.[4]
Do not assume that a treatment called “stem cell therapy” has one fixed national clinic price. Ask for the fee for the exact treatment, dose, treatment site, and number of administrations proposed for you.
Own Cells or Donor Cells
Autologous treatment uses the patient’s own cells. For adipose-derived MSCs, fat has to be collected and processed. Bone-marrow-derived treatment can require bone marrow collection. These steps add medical staff, procedure time, equipment, sample handling, and laboratory work.
Donor-derived, or allogeneic, cells can avoid personal tissue collection, but the cost shifts to areas such as donor controls, manufacturing, testing, storage, and supply.
PMDA publishes separate quality and safety guidance for autologous and allogeneic cell- and tissue-based regenerative medical products.[5]
Neither approach is automatically cheaper. When two quotes use different cell sources, check the autologous vs allogeneic stem cell comparison before comparing the numbers.
Add Collection Costs
In one MHLW-published knee plan, about 20–30 mL of fat tissue is collected from the abdomen or buttock. Local anesthetic is used, a small incision is made, and the tissue is sent for cell processing.[1]
The same plan lists about ¥1,000,000 per knee for 100 million cells, including cell culture and storage. If another fat collection is required because the needed cell number was not obtained, the document lists an additional ¥100,000 collection fee.[1]
¥100,000 is 10% of the original ¥1,000,000 headline figure. A repeat collection can therefore make a noticeable difference to the final bill.
The ¥100,000 amount belongs to that specific treatment plan. It is not a standard repeat-collection fee across Japan.
Count the Lab Work
In the same MHLW knee document, the collected tissue is processed to isolate cells. The cells are then increased over several weeks to about one month until the required number is reached.[1]
The administration itself may take part of a day, while the cell-processing stage can run for several weeks. The quote may therefore include work the patient never sees directly:
- trained processing staff;
- controlled processing facilities;
- culture materials;
- storage;
- transport;
- contamination controls;
- quality checks;
- record keeping.
The MHLW document states that the cell solution is checked for harmful contamination before use, including bacteria, fungi, viruses, and pyrogenic substances, with sterility testing described in the treatment process.[1]
The exact test panel is not the same for every treatment. PMDA also publishes technical material covering areas such as sterility and mycoplasma testing for regenerative medical products.[5]
Ask what checks apply to your cells, what must pass before administration, and what happens if the preparation cannot be used. The CPC cell processing center guide covers processing, storage, release checks, and traceability in more detail.
Do Not Price by Cell Count
The two MHLW knee examples both state 100 million cells. One lists about ¥1,000,000 and the other lists ¥1,400,000 including tax.[1][2]
Dividing those figures by the stated cell count gives about ¥10,000 per million cells in the first example and ¥14,000 per million cells in the second.
The arithmetic is correct, but the comparison is not very useful. It ignores collection, cell preparation, treatment site, tax, storage, clinic policy, and follow-up.
Instead, ask:
- How many cells will actually be administered each time?
- Is the number per administration or for the whole course?
- Why was this dose chosen?
- Are the two clinics using the same type of cell preparation?
Check the Price Unit
A price can be quoted:
- per knee;
- per joint;
- per injection;
- per infusion;
- per treatment date;
- per treated site;
- or for the full course.
The first MHLW example is about ¥1,000,000 per knee for 100 million cells.[1]
The second states ¥1,400,000 including tax per administration for 100 million cells.[2]
A patient treating both knees should not assume that a one-knee price automatically covers both sides. The clinic should state the number of joints or treatment sites included in writing.
For orthopedic treatment, the knee joint disorders guide helps separate the medical condition from the pricing question.
Price the Full Course
The MHLW chronic-pain document lists:
- ¥5,000 for the initial consultation;
- ¥1,800,000 before tax for one treatment;
- the same ¥1,800,000 fee for later treatments when additional treatment is considered.
The stated treatment fee includes cell-processing costs, collection and administration procedure fees, and follow-up consultation fees.[3]
| Planned treatments | Treatment fees before tax | Plus initial consultation |
|---|---|---|
| 1 | ¥1,800,000 | ¥1,805,000 |
| 2 | ¥3,600,000 | ¥3,605,000 |
| 3 | ¥5,400,000 | ¥5,405,000 |
These calculations do not mean every patient receives two or three treatments. They show how quickly a per-treatment price changes once more than one administration is planned.
Ask the clinic for the number of administrations currently expected and the total cost of that plan.
Add Pre-Treatment Tests
Depending on the condition and protocol, treatment may require:
- medical history and current medicine review;
- blood tests;
- infection screening;
- MRI, CT, X-ray, or other imaging;
- specialist assessment;
- disease-specific testing.
The MHLW knee plan describes an eligibility stage that can include blood testing and, when needed, ECG and X-ray testing before treatment proceeds.[1]
A website price may therefore change after the doctor reviews the patient’s records.
International patients should ask whether recent tests from their home country can be used. Repeating an MRI, CT scan, blood panel, or specialist consultation in Japan can add both cost and extra days.
The stem cell therapy indications and contraindications guide explains why eligibility cannot be decided from the treatment name alone.
Read the Quote Line by Line
| Item | What to confirm |
|---|---|
| Doctor consultation | Included or separate? |
| Blood tests and imaging | Included or separate? |
| Tissue collection | Included or separate? |
| Cell processing and culture | Included or separate? |
| Cell testing | Included or separate? |
| Cell storage | How long is included? |
| Administration | How many treatments are included? |
| Medication | Included or separate? |
| Follow-up | How many visits or checks? |
| International support | Separate from the medical fee? |
| Tax | Already included or added later? |
The ¥1,400,000 knee example explicitly states that tax is included. The ¥1,800,000 chronic-pain example is stated before tax.[2][3]
A quote that says “¥1,400,000” and another that says “¥1,400,000 before tax” are not the same final bill.
Check Storage Terms
The chronic-pain MHLW document states that prepared cells can be frozen and stored in liquid nitrogen for up to one year. It also states that a reference portion is stored at −80°C for six months after administration.[3]
Do not assume every clinic includes the same storage period.
- How long is storage included in the quote?
- Is there a fee to keep the cells longer?
- Is preparation for another treatment charged separately?
- What happens to cells that are not used?
Know the Failure and Refund Rules
The ¥1,000,000 knee plan states that if contamination with bacteria or fungi occurs during collection or culture, the cultured cells are discarded and another collection may be considered.[1]
If another collection is needed because the necessary cell number was not obtained, the same plan lists an extra ¥100,000 fat-collection fee. That adds 10% to the ¥1,000,000 headline figure.[1]
The ¥1,400,000 plan also states that contaminated cells may need to be discarded. If the contamination is caused by the clinic or processing facility, the document says another fat collection can be discussed without an additional charge.[2]
Both knee documents warn that part of the payment may no longer be refundable once fat collection has taken place.[1][2]
Before paying, get written answers to these points:
- Who pays if another collection is needed?
- Which processing costs become non-refundable?
- What happens if the cells fail the clinic’s release checks?
- What is refunded if no cells are administered?
Count Follow-Up Visits
The chronic-pain MHLW document asks patients to cooperate with follow-up at about 1 month, 3 months, and 6 months after the final treatment. That gives three planned follow-up points within the first six months. Telephone follow-up can be used when regular clinic visits are difficult.[3]
The same document states that patients are observed in the clinic for about one hour after cell administration.[3]
Ask how many later checks are included, whether remote follow-up is available, and whether additional imaging or blood tests are charged separately.
Check Complication Costs
The ¥1,400,000 knee-treatment document states that medical costs for health damage suspected to be related to the regenerative medicine treatment are covered by the medical institution, including costs incurred at another medical institution.[2]
The chronic-pain document describes its own arrangements and states that necessary treatment and emergency transport costs are covered when the health problem is considered related to the treatment.[3]
These are plan-specific policies, not one national rule.
Overseas patients should ask what happens if a possible treatment-related problem appears after they return home. The stem cell therapy safety guide covers the medical side of this question.
Separate Medical and Support Fees
International-patient charges can include:
- medical interpretation;
- record translation;
- remote document review;
- international-patient coordination;
- medical certificates;
- additional scheduling and communication.
MHLW publishes a dedicated manual on calculating self-pay medical prices for visiting foreign patients.[4]
Ask for two separate figures:
medical treatment cost
and
international-patient support cost.
This shows whether a higher package price comes from the medical procedure or from translation and coordination services.
Add Travel to the Total
Autologous cultured-cell treatment can require separate collection and administration dates. In the MHLW knee example, culture takes several weeks to about one month.[1]
For a patient travelling to Japan, another visit can mean another flight, hotel stay, local transport, and time away from work.
Before booking, confirm:
- the collection date;
- expected culture period;
- administration date;
- required stay after treatment;
- whether the date can change if processing takes longer;
- whether follow-up requires another trip.
The medical travel guide for stem cell treatment in Japan covers these timing and travel issues.
Verify the Regulatory Route
A regenerative medicine provision plan is not the same thing as a PMDA-approved regenerative medical product.
PMDA explains that Japan uses separate regulatory frameworks. The Act on the Safety of Regenerative Medicine covers regenerative medicine in research and medical practice, while the PMD Act regulates the commercialization of regenerative medical products.[5]
MHLW’s e-Regenerative Medicine system explains the procedures for regenerative medicine provision plans and provides public information on submitted plans.[6]
If a clinic uses the word “approved,” ask:
- Is this a PMDA-approved regenerative medical product?
- Or is the treatment being provided under a regenerative medicine provision plan?
- What exact treatment and condition does that approval or plan cover?
The Japan regenerative medicine registration and compliance guide explains how to check the difference.
Keep Evidence Separate from Price
A higher bill can come from collection, culture, storage, more treatment sessions, additional tests, or longer follow-up. None of those costs proves that the treatment works better.
ISSCR advises patients considering stem cell interventions to check the scientific evidence, risks, alternative treatments, regulatory status, financial costs, and follow-up arrangements.[7]
If a clinic shows you a study, check whether it matches:
- your diagnosis;
- the same cell source;
- a similar dose;
- the same administration route;
- a similar treatment schedule;
- a similar patient group.
Then check the number of patients, whether there was a comparison group, what result was measured, and how long patients were followed.
Research on one cell treatment for one disease does not prove that another cell treatment will work for a different disease.
Compare Real Published Prices
| Published example | Price | Useful detail |
|---|---|---|
| Autologous adipose-derived MSCs for knee osteoarthritis | About ¥1,000,000 per knee for 100 million cells | Culture and storage included; another fat collection can cost ¥100,000 if needed |
| Another autologous adipose-derived cell treatment for knee osteoarthritis | ¥1,400,000 including tax per 100-million-cell administration | Culture and storage included; some payment is non-refundable after fat collection |
| Autologous adipose-derived stem cell treatment for chronic pain | ¥1,800,000 before tax per treatment + ¥5,000 initial consultation | Later treatments use the same treatment fee; processing, collection, administration, and follow-up consultation costs are included |
The first example comes from one MHLW-published knee plan.[1] The second comes from another knee-treatment plan.[2] The third comes from a chronic-pain treatment document.[3]
The two knee plans both mention 100 million cells but differ by ¥400,000, or 40%, at the headline level. The chronic-pain plan uses a different indication and pricing structure. These three numbers should not be treated as three prices for one standard treatment.
Compare Quotes Side by Side
| Question | Clinic A | Clinic B |
|---|---|---|
| Exact treatment | ||
| Cell source | ||
| Own or donor-derived cells | ||
| Collection required | ||
| Cells cultured | ||
| Cell dose per treatment | ||
| Price unit | ||
| Number of treatments | ||
| Tests included | ||
| Storage included | ||
| Follow-up included | ||
| Repeat-collection fee | ||
| Failed-processing policy | ||
| Refund terms | ||
| International support fees | ||
| Tax included? | ||
| Total expected cost |
If the two columns contain different cell sources, doses, numbers of treatments, or included services, the headline prices are not yet a fair comparison.
The same checks are useful when deciding how to compare stem cell hospitals in Japan.
Watch for These Red Flags
- The clinic cannot clearly identify the cells being used.
- The clinic will not explain whether or how the cells are processed.
- A high cell count is used as the main proof that the treatment is better.
- The price does not state whether it is per joint, session, or course.
- The clinic will not provide a written total cost.
- The clinic cannot explain what happens if cell processing fails.
- Cancellation or refund terms are unclear.
- A regenerative medicine provision plan is presented as proof that treatment effectiveness has been established.
- The clinic guarantees improvement.
- Treatment is recommended before the diagnosis and relevant medical information are properly reviewed.
ISSCR advises patients to examine evidence, risks, treatment details, financial costs, and emergency arrangements before agreeing to an unproven stem cell intervention.[7]
Ask Before Paying
- What exact cells will I receive?
- Are they my own cells or donor-derived?
- Will tissue collection be required?
- Are the cells cultured, and roughly how long does processing take?
- What cell dose will I receive each time?
- Is the price per knee, joint, injection, infusion, session, or full course?
- How many treatments are currently planned?
- Which tests, processing, storage, and follow-up costs are included?
- How long is cell storage included?
- What happens if the required cell number is not reached?
- What happens if the cells fail quality checks?
- Who pays if another collection is required?
- Which payments become non-refundable after collection or culture starts?
- What is the expected total cost including tax and international-patient fees?
FAQ
Why can two clinics charge different prices for 100 million stem cells?
Two MHLW knee plans both mention 100 million cells, but their published figures are about ¥1,000,000 and ¥1,400,000. That is a 40% headline difference.[1][2] Cell count is only one part of the bill. Collection, processing, storage, treatment site, tax, follow-up, and clinic policy can also differ.
Is the quoted price for one treatment or the full course?
Do not assume either. A quote may be per knee, per administration, or per course. In the chronic-pain example, one treatment is ¥1,800,000 before tax and later treatments are listed at the same fee. Two treatments would total ¥3,600,000 before tax in treatment fees, while three would total ¥5,400,000.[3]
How long can cell processing take?
It depends on the treatment. In one MHLW-published autologous adipose-derived MSC knee plan, cell expansion takes several weeks to about one month before the required cell number is reached.[1] Another treatment may use a different process.
Can failed cell processing create extra costs?
Yes, depending on the treatment plan. In the ¥1,000,000 knee example, another fat collection can cost ¥100,000 when the required cell number is not obtained. That is 10% of the original headline figure. Another plan describes no-charge repeat collection in certain cases when contamination is caused by the clinic or processing facility.[1][2]
Do international patients always pay the same amount as Japanese patients?
Do not assume so. Interpretation, translation, coordination, and other international-patient services may be charged separately. MHLW publishes guidance specifically for medical institutions calculating self-pay prices for visiting foreign patients.[4]
Does a higher price mean stronger evidence?
No. Collection, culture, storage, several treatment sessions, and longer follow-up can all raise the bill without proving that the treatment works better. Evidence should match the exact disease, cell source, dose, route, and treatment plan. ISSCR recommends checking these issues separately from treatment cost.[7]
Finally
Three public Japanese treatment plans show why the headline figure can be misleading: about ¥1,000,000 per knee for 100 million cells, ¥1,400,000 including tax per 100-million-cell administration, and ¥1,800,000 before tax per chronic-pain treatment.[1][2][3] A repeat fat collection in the first plan can add ¥100,000, while two ¥1.8 million treatments reach ¥3.6 million before tax. Compare the exact cell source, dose, price unit, number of treatments, collection and culture costs, tests, storage, follow-up, refund rules, tax, and international-patient fees. That is the number that matters: the expected total cost of the treatment actually being proposed.